Clinical Trials Logo

Liver Neoplasms clinical trials

View clinical trials related to Liver Neoplasms.

Filter by:

NCT ID: NCT00532740 Completed - Metastatic Cancer Clinical Trials

Radiolabeled Glass Beads in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery

Start date: December 2004
Phase:
Study type: Observational

RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be effective treatment for liver cancer that cannot be removed by surgery. PURPOSE: This phase II trial is studying how well radiolabeled glass beads work in treating patients with metastatic liver cancer that cannot be removed by surgery.

NCT ID: NCT00530010 Completed - Liver Cancer Clinical Trials

Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Start date: December 2004
Phase:
Study type: Observational

RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be effective treatment for liver cancer that cannot be removed by surgery. PURPOSE: This phase II trial is studying how well radiolabeled glass beads work in treating patients with liver cancer that cannot be removed by surgery.

NCT ID: NCT00527891 Completed - Liver Cancer Clinical Trials

Evaluation of the Signa Excite 3.0 T MRI Excite for Detection and Characterization of Liver Lesions

Start date: June 2004
Phase: Phase 1
Study type: Observational

Primary Objective: 1. To compare the efficacy of 1.5T vs. 3T T1 and T2-weighted MR images sequences for the detection and evaluation of liver lesions.

NCT ID: NCT00524316 Terminated - Liver Cancer Clinical Trials

Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Start date: April 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs, such as doxorubicin, near the tumor. Giving sunitinib together with chemoembolization may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving sunitinib together with chemoembolization works in treating patients with liver cancer that cannot be removed by surgery.

NCT ID: NCT00522509 Active, not recruiting - Clinical trials for Colorectal Liver Metastases

Preoperative Hepatic Arterial Infusion Chemotherapy

Start date: December 1995
Phase: N/A
Study type: Observational

To assess the feasibility and results of liver resection after preoperative hepatic artery infusion (HAI) chemotherapy with FUDR.

NCT ID: NCT00514930 Recruiting - Liver Cancer Clinical Trials

Multicentre Prospective Clinical Trial for RFA Tumour Aspirator Treatment of Primary and Secondary Malignancies of the Liver

Start date: February 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The primary aim for this trial is to assess whether the RFA aspirator device is safe and of clinical benefit in patients with primary or secondary malignant liver tumours

NCT ID: NCT00514228 Completed - Liver Cancer Clinical Trials

Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Start date: July 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with liver cancer that cannot be removed by surgery.

NCT ID: NCT00513461 Completed - Clinical trials for Hepatitis C Infection

Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection

Start date: October 2007
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) works compared to a placebo in preventing liver cancer in patients with chronic hepatitis C infection. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of SAMe may keep cancer from forming in patients with advanced liver disease

NCT ID: NCT00510627 Withdrawn - Clinical trials for Metastatic Liver Cancer

Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases

Prometheus
Start date: August 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether patients treated with Radiofrequency Ablation (RFA) in conjunction with chemotherapy have a better overall survival rate than patients treated with chemotherapy alone.

NCT ID: NCT00508872 Terminated - Clinical trials for Colorectal Liver Metastases

Folfox-B Study for Patients With Colorectal Liver Metastases

Start date: November 2005
Phase: Phase 2
Study type: Interventional

Objective: - To evaluate the efficacy of the use of the combination of oxaliplatin, 5-fluorouracil, leucovorin and bevacizumab (FOLFOX-B) in patients with unresectable colorectal liver metastases, with the objective to downstage hepatic disease and enable complete resection of residual disease. Primary Objective: - To evaluate the resection rate in patients with initially unresectable hepatic colorectal metastases downstaged with FOLFOX-B. Complete resection of all liver lesions is the goal. Secondary Objectives: - To evaluate the probability of complete response, partial response or stable disease. - To evaluate the proportion of patients who are resected, and the proportion of patients achieving an R0 resection (among those receiving surgery). - To correlate survival with downstaging and resection based on metastatic colorectal prognostic score. - To evaluate the disease-free survival and overall survival. - To evaluate the positron emission tomography response rate. - To explore correlations of clinical response with telomerase and hTERT expression.